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Abstract
Background and Objectives Trastuzumab (Herceptin) is
a humanized monoclonal antibody (mAb) that binds to the
HER2 protein. PF-05280014 is being developed as a potential
biosimilar to trastuzumab products marketed in the United
States (trastuzumab-US) and European Union (trastuzumab-
EU). Nonclinical studies were designed to evaluate the sim-
ilarity of PF-05280014 to trastuzumab-US and trastuzumab-
EU using in vitro structural and functional analyses, and
in vivo pharmacokinetic and immunogenicity assessments.
Methods Peptide mapping was utilized to determine
structural similarity. Functional similarity was assessed via
an in vitro tumor cell growth inhibition assay. CD-1 male
mice were administered a single-dose (0, 1, 10, or 100 mg/
kg) of PF-05280014, trastuzumab-US, or trastuzumab-EU.
Mice were monitored for clinical signs and body weight
changes over a 4-month period. At approximately 720,
1,080, 1,440, 2,160, and 2,880 h post-dose, terminal blood
samples were collected and assayed for PF-05280014,
trastuzumab-US, or trastuzumab-EU concentrations and
anti-drug antibodies (ADA). Values for Cmax, area under
the concentration time curve (AUC), clearance (CL), vol-
ume of distribution (Vss), half-life (t), and the presence of
ADA were determined.
Results In this report, peptide mapping of PF-05280014,
trastuzumab-US, and trastuzumab-EU showed similar
chromatographic profiles in a side-by-side analysis. The
tumor cell growth inhibition of PF-05280014 was similar to
trastuzumab-US and trastuzumab-EU. Cmax and AUC0–?
values in mice were similar and dose-dependent across the
mAbs at all doses, and CL and Vss values were similar and
dose-independent. The CL values across doses ranged from
0.193 to 0.350 mL/h/kg (PF-05280014), from 0.200 to
0.346 mL/h/kg (trastuzumab-US), and from 0.193 to
0.335 mL/h/kg (trastuzumab-EU). Vss values across doses
ranged from 84.9 to 120 mL/kg (PF-05280014), 86.7 to
130 mL/kg (trastuzumab-US), and 85.4 to 116 mL/kg
(trastuzumab-EU). The incidence of ADA was low
(*10%) and also similar across all dose levels and the
three mAbs. The lower exposure generally observed in
ADA-positive animals did not impact the overall
PK interpretation. All animals survived to their scheduled
terminal blood collection with no mAb-related differences
in body weight gain or clinical signs.
Conclusions PF-05280014, trastuzumab-US, and trast-
uzumab-EU were well tolerated during the 4-month
observation period following a single dose of up to
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100 mg/kg. PF-05280014, trastuzumab-US, and trast-
uzumab-EU showed similar structural properties, tumor
cell growth inhibition properties, and PK profiles. The
incidence of ADA was low and similar across the three
mAbs. The results of these studies support the development
of PF-05280014 as a proposed biosimilar to Herceptin.
Key Points
PF-05280014, trastuzumab-US, and trastuzumab-EU
were all well tolerated following a single dose of up
to 100 mg/kg.
PF-05280014, trastuzumab-US, and trastuzumab-EU
showed similar structural properties, tumor cell
growth inhibition properties, and PK profiles.
The results of the evaluated studies support the
development of PF-05280014 as a proposed
biosimilar to the marketed trastuzumab products
(Herceptin).
1 Introduction
Trastuzumab (Herceptin) is a humanized recombinant IgG1
monoclonal antibody (mAb) that selectively inhibits signal-
ing of the human epidermal growth factor receptor 2 (HER2)
[1]. Herceptin is licensed in the United States (US) [2] and
approved in the European Union (EU) [3] for the treatment of
HER-2-overexpressing breast and gastric cancers. The mar-
keted products obtained from these two regions are referred to
herein as trastuzumab-US and trastuzumab-EU, respectively.
There is evidence that treatment with Herceptin blocks
intracellular signaling, causes cytostatic G1 arrest, and
induces growth inhibition in target cells [1, 4]. Like many
other licensed or approved biotherapeutics products, trast-
uzumab is nearing the expiration of at least one of its patents,
allowing development of biosimilar drug therapies.
Regulatory agencies in the EU and the US have devel-
oped final or draft specific guidance documents describing
their criteria for a biologic to be considered a biosimilar
[5–9]. Biosimilars are biologic drugs designed to be highly
similar to the licensed or approved biologic product (‘‘the
reference product’’) in regards to key analytic (e.g., struc-
tural identity, potency, and in vitro functions), nonclinical
(e.g., pharmacokinetic, immunogenicity, safety and toler-
ability profiles), and clinical (e.g., pharmacokinetics,
pharmacodynamics, immunogenicity, efficacy, safety and
tolerability) profiles [4–8]. Unlike small molecule generic
drugs that are identical to the licensed or approved
reference drug, biosimilars are highly similar, but not
identical, to the reference drug. Manufacturing processes
for biologics typically are proprietary, and without access
to this information other pharmaceutical companies have to
produce biosimilars using existing technology to reverse
engineer the biosimilar to be highly similar to the reference
product profile [5–9]. These regulatory and scientific
guidances have indicated that the in-depth physicochemical
and functional characterization of a proposed biosimilar
should include appropriately robust and orthogonal ana-
lytical methods that enable a comprehensive molecular,
functional, and structural biosimilarity assessment [10–12].
PF-05280014 is a humanized recombinant IgG1 mAb
directed against the extracellular domain of the HER2 receptor
being developed as a potential biosimilar of the reference
products marketed as Herceptin in the US and EU (trast-
uzumab-US and trastuzumab-EU, respectively). In nonclinical
studies, these reference products have been shown to induce
apoptosis in human tumor cell lines overexpressing HER2 and
shrink tumor xenograft implants in athymic mice [13–15].
Furthermore, since trastuzumab does not recognize the mouse
counterpart of human HER2 [16], non-target-mediated and
FcRn-dependent clearance of PF-05280014, trastuzumab-US,
and trastuzumab-EU can be compared in mice [17]. During the
development of PF-05280014, the proposed biosimilar was
subjected to extensive side-by-side physicochemical and
functional characterization using state of the art robust and
orthogonal methodologies with reference product Herceptin
sourced from the US and the EU (Ng et al. manuscript in
preparation). The focus of the current manuscript is to report
the nonclinical comparisons including in vivo pharmacoki-
netics (PK), anti-drug antibody (ADA) responses, and tolera-
bility of PF-05280014, trastuzumab-US, and trastuzumab-EU.
In addition, we report the comparative in vitro peptide maps
and tumor cell growth inhibition properties.
2 Methods
2.1 Physicochemical and Functional Similarity
We determined the level of physicochemical similarity
between PF-05280014, trastuzumab-US, and trastuzumab-
EU by generating individual tryptic peptide maps for the
three mAbs. The trypsin-digested peptides for each mAb
were separated on a reversed-phase high performance
liquid chromatography using a 2.1 9 150 mm Waters
BioSuite C18 column (Waters Corp., Milford, MA) mon-
itored at 214 nm. Each peptide was identified by liquid
chromatography mass spectrometry using ultrahigh reso-
lution quadrupole time-of-flight mass spectrophotometer.
To determine the level of in vitro functional similarity,
PF-05280014, trastuzumab-US, and trastuzumab-EU were
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analyzed in an in vitro tumor cell proliferation inhibition
assay using the HER2-overexpression metastatic breast
carcinoma cell line, SKBR-3. Cellular viability was
detected using CellTiter Glo (Promega, Inc., Madison, WI),
a commercially available bioluminescent detection kit
designed to measure mammalian cell viability through the
presence of ATP present in live cells [18]. Briefly, SKBR-3
cells derived from a metastatic breast adenocarcinoma that
over-expresses the HER2 receptor were seeded into a
96-well tissue culture treated plates and cultured for 24 h.
The media from the cell plate was removed and serially
diluted PF-05280014, trastuzumab-US, or trastuzumab-EU
were transferred into the appropriate wells. Inhibition of
cell growth was inversely proportional to the amount of
ATP present in each well, as determined by measuring
luminescence using the CellTiter Glo detection kit. The
resulting dose-response curves for the three mAbs allowed
determination of their relative potency with respect to each
other.
2.2 Animals
Male CD-1 mice (Charles River Laboratories, Portage, MI)
were used in the in vivo PK/tolerability study; the strain
was selected to match data available for the reference
products. There were ten groups (one control group, and
three groups for each mAb at doses of 1, 10, or 100 mg/
kg), each containing 55 mice. At the initiation of dosing,
animals were 6–7 weeks old and weighed between 25.5
and 43.4 g. This in vivo study was designed to provide data
to support the subsequent clinical development of
PF-05280014 as a potential biosimilar.
2.3 Dose Preparation, Dose Analysis, and Dose
Administration
To achieve the dose levels of 1, 10, and 100 mg/kg with a
dose volume of 5 mL/kg, PF-05280014 stock solution
(22 mg/mL) was diluted in histidine/sucrose buffer. Both
trastuzumab-US and trastuzumab-EU, as lyophilized
commercial products, were first reconstituted in sterile
water for injection according to the product label to
achieve the label concentration of 21 mg/mL, and then
further diluted in histidine/trehalose buffer. The control
group was administered PF-05280014 diluent and each of
the other groups received one of the three mAbs at 1, 10, or
100 mg/kg by bolus intravenous (IV) injection into the tail
vein.
The mAb dose concentrations were verified by ultra-
violet spectrophotometry by measuring absorbance at
280 nm [19]. Stability of the formulations under these
conditions was confirmed. All dose preparations were
within ±10 % of the target concentrations (mean values
ranging from 102.3 to 105.0 % of target), with the
exception of the 2.0 mg/mL PF-05280014 formulation
(mean 114.3 % of target). Because this deviation was
small (14 %, compared to the ±10 % acceptable range)
and dose-normalized PK data demonstrated that the
interpretation of the exposure data was not impacted by
this change, the nominal dose (10 mg/kg) was used for
this group. The doses (1, 10, and 100 mg/kg) were
selected to match PK data available for the reference
products.
2.4 Pharmacokinetics
Because blood from each mouse was collected via terminal
cardiac puncture, only one sample per mouse was obtained.
Thus, composite profiles for each mAb were generated for
PK evaluation. Samples were collected at approximately
0.5, 6, 24, 96, 168, 336, 720, 1,080, 1,440, 2,160, and
2,880 h post-dose in each group. Five animals/group/time
point were anesthetized with carbon dioxide inhalation and
at least 0.7 mL of blood was collected via cardiac puncture
from each animal; necropsy was not performed. Blood
samples were allowed to clot at room temperature, and the
serum was harvested following centrifugation and stored at
-60 to -80 C until analyzed.
Serum concentrations of trastuzumab were determined
via a single validated enzyme-linked immunosorbent assay
(ELISA) that was cross-validated for PF-05280014, trast-
uzumab-US, and trastuzumab-EU. PF-05280014, trast-
uzumab US, or trastuzumab EU was captured using
recombinant HER2 extracellular domain adsorbed on a
microtiter plate. Bound trastuzumab was detected using a
goat anti-human immunoglobulin (IgG) antibody conju-
gated with horseradish peroxidase. The substrate, 3,30,5,50
tetramethylbenzidine, was used for the colorimetric read-
out. Sample concentrations were determined by interpola-
tion from a calibration curve that was fit using a five
parameter logistic model (1/y2 weighting). The lower limit
of quantitation was 20.0 ng/mL. Concentration values
below the lower limit of quantitation were considered to
equal zero for descriptive statistics and PK analyses.
Noncompartmental PK analysis was performed on mean
serum concentration data using WinNonlin Professional
Edition (Pharsight Corporation, Version 5.2, Mountain
View, CA) with nominal doses and sampling times to
generate the composite PK profile for each mAb. Param-
eters included maximum serum concentration of the
administered mAb (Cmax), area under the concentration-
time curve (AUC), elimination half-life (t1/2), systemic
clearance (CL), and volume of distribution at steady-state
(Vss).
The serum AUC to a specified time point (AUC0–2,880)
and total exposure (AUC0–?) were estimated using the
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linear trapezoidal rule [20]. The percent extrapolation in
the AUC0–? calculations was determined as follows:
[(AUC0–?) - AUC0–2,880)/AUC0–?] 9 100. This per-
cent extrapolation calculation was used to determine if the
AUC0–2,880 values were representative of the overall pre-
dicted concentration-time curves.
2.5 Anti-drug Antibody Detection
Samples for ADA testing consisting of approximately
0.12 mL of whole blood were collected from each animal in
the PF-05280014, trastuzumab-US, and trastuzumab-EU
groups prior to dosing and at one time point/animal after
dosing. Pre-dose samples were collected via submandibular
puncture and post-dose samples were collected via cardiac
puncture at approximately 720, 1,080, 1,440, 2,160, or
2,880 h post-dose. All samples were allowed to clot at room
temperature. The serum was harvested following centrifu-
gation and was stored at -60 to -80 C until analyzed. Pre-
dose (baseline) and terminal time point serum samples were
analyzed for the presence of ADA using validated electro-
chemiluminescence assays (Meso Scale Discovery, Rock-
ville, MD) specific for PF-05280014, trastuzumab-US, or
trastuzumab-EU. These samples were used to generate
composite profiles for each administered mAb.
The positive control (affinity purified rabbit anti-trast-
uzumab-EU IgG), negative control (pooled normal CD-1
mouse serum), and study serum samples were co-incu-
bated with biotinylated PF-05280014 and ruthenium-
labeled PF-05280014, or biotinylated trastuzumab-US and
ruthenium-labeled trastuzumab-US, or biotinylated trast-
uzumab-EU and ruthenium-labeled trastuzumab-EU (to
match the mAb administered to each individual animal).
Anti-drug antibodies were captured via the biotinylated-
PF–05280014, biotinylated-trastuzumab-US, or biotiny-
lated-trastuzumab-EU using streptavidin-coated Meso
Scale Discovery Multi-Array plates. Final detection was
achieved using ruthenylated-trastuzumab and tripropyl-
amine to produce an electrochemiluminescent signal that
was measured using the Meso Scale Discovery SectorTM
Imager 6000. Assay responses were quantified in relative
light units (RLU). To ensure that ADA induction was
being measured, the pre-dose (baseline) sample served as
the control for each animal. Samples that were negative
post-dose were considered negative for ADA whether or
not the pre-dose sample was also negative. Samples that
were negative pre-dose and positive post-dose were con-
sidered positive for ADA induction. Samples that were
positive both pre- and post-dose were considered positive
if the post-dose titer was at least one dilution factor higher
(0.3 or log 2, where 2 was the serial dilution factor)
compared with the titer value for corresponding pre-dose
sample. Trastuzumab was not detected in any of the
control samples; thus, samples from the control group
were not evaluated for ADA.
2.6 In-Life Observations
Animals were checked twice daily for mortality, signs of
pain or distress, and any other abnormalities. Cage-side
observations were performed 2 and 4 h after dosing
(including an examination of the injection site), and once
daily throughout the 4-month (2,880 h) observation period.
Body weights were recorded prior to dosing and weekly
throughout the study. Overall assessment of tolerability
was based on mortality, clinical signs, body weight, and
body weight change.
3 Results
3.1 Biochemical and In vitro Functional Properties
The tryptic peptide map for PF-05280014 was similar to
those obtained for trastuzumab-US and trastuzumab-EU
(Fig. 1). The detected peptides constitute at least 98 % of
the amino acid sequence of trastuzumab. The small portion
(\2%) of the antibody sequence that was not detected
corresponds to small peptides that are not retained on the
analytical chromatographic column. The complete amino
acid sequence, including those small peptides not observed
in the tryptic peptide map, was confirmed in a separate LC/
MS analysis at the subunit level (Ng et al. manuscript
detailing extensive structural and functional biosimilarity
characterization in preparation) for each mAb. These
results demonstrate that the primary sequences of
PF-05280014, trastuzumab-US, and trastuzumab-EU were
identical in peptide sequence to each another.
In the tumor cell growth inhibition assay using SKBR-3
cells, the dose-response curves for PF-05280014, trast-
uzumab-US, and trastuzumab-EU were superimposable
(Fig. 2). These data indicate that PF-05280014 is similar to
trastuzumab-US and trastuzumab-EU in both its amino acid
sequence and expected in vitro antiproliferative properties.
3.2 In-Life Observations
All animals survived until their scheduled terminal PK time
point. There were no mAb-related clinical signs or effects
on mean body weight or body weight change in any of the
dose groups.
3.3 Pharmacokinetics
PF-05280014, trastuzumab-US, and trastuzumab-EU
demonstrated similar serum concentration profiles over the
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first 24 h at all three doses evaluated (Fig. 3) and through
2,880 h (Fig. 4). PK parameters Cmax, AUC0–2,880, AUC0–
?, t1/2, CL, and Vss were also similar across the three mAbs
(Table 1). The percent extrapolation in the AUC0–? values
based on the AUC0–2,880 values ranged from 0.081 % to
1.28 %, indicating minimal extrapolation of these data.
Both CL and Vss appeared to be independent of the
administered dose for all three mAbs. The t1/2 for PF-
05280014 was similar to, and generally overlapped with,
the t1/2 of trastuzumab-US and trastuzumab-EU. When data
from mice that tested positive for ADA were excluded
from the mean calculations, there was no impact on the
overall PK interpretation (Table 2). Comparisons of the
Cmax and AUC ratios indicate that PF-05280014 had sim-
ilar exposures to trastuzumab-US and trastuzumab-EU at
all three doses regardless of whether data from all mice
were used for the comparisons or when data from samples
from those mice testing positive for ADA were excluded
(Table 3).
3.4 Anti-Drug Antibodies
Induction of ADA in animals was determined by comparing
the pre-dose (baseline) and post-dose serum ADA results in
the same animal. Following administration of PF-05280014,
trastuzumab-US, or trastuzumab-EU, the overall incidence of
ADA in mice was low. Specifically, 8/74 (10.8 %), 6/75
(8 %), and 8/75 (10.7 %) of the animals tested positive for the
induction of antibodies against PF-05280014, trastuzumab-
US, and trastuzumab-EU, respectively (Table 4). Most
animals that tested positive for the induction of anti-PF-
05280014, anti-trastuzumab-US, or anti-trastuzumab-EU
antibodies at 720, 1,080, 1,440, 2,160 or 2,880 h post-dose
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Fig. 1 Comparison of tryptic



























Fig. 2 Comparison of in vitro
functional activity of PF-
05280014 with trastuzumab-US
and trastuzumab-EU measured
in tumor cell growth inhibition
assay using SKBR-3 cells
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that tested negative, although this correlation could not be
made for every animal that tested positive.
4 Discussion
In vitro evaluation of PF-05280014, trastuzumab-US,
and trastuzumab-EU demonstrated that all three mAbs
have the identical amino acid sequences based on a
comparison of their tryptic peptide maps and LC/MS
data. The in vitro tumor cell growth inhibition curves
for PF-05280014, trastuzumab-US, and trastuzumab-EU
were also superimposable. Taken together, these data
demonstrate that PF-05280014 is identical to trast-
uzumab-US and trastuzumab-EU in sequence identity,
and similar to them in its in vitro tumor cell growth

























Fig. 3 Mean (±SD)
concentrations of PF-05280014,
trastuzumab-US, or
trastuzumab-EU over 24 h after
a single bolus intravenous
injection of 1, 10, and 100 mg/
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Fig. 4 Mean (±SD)
concentrations of PF-05280014,
trastuzumab-US, and
trastuzumab-EU over time for
the whole study duration up to
2,880 h after a single bolus
intravenous injection of 1, 10,
and 100 mg/kg in male CD-1
mice
















PF-05280014 1 22.8 ± 1.90 4,200 ± 287 4,220 380 0.237 104
10b 318 ± 49.4 51,400 ± 1,560 51,800 440 0.193 84.9
100 2,520 ± 219 285,000 ± 11,000 286,000 309 0.350 120
Trastuzumab-US 1 26.3 ± 5.83 4,050 ± 334 4,080 416 0.245 129
10 269 ± 52.7 49,800 ± 1,430 50,000 352 0.200 86.7
100 2,620 ± 332 289,000 ± 12,500 289,000 320 0.346 130
Trastuzumab-EU 1 18.6 ± 8.55 4,590 ± 337 4,650 536 0.215 113
10 281 ± 49.9 51,500 ± 1,370 51,800 392 0.193 85.4
100 2,700 ± 450 298,000 ± 10,300 298,000 280 0.335 116
a The percent extrapolation in the AUC0–? values ranged from 0.081 to 1.28 %;
b nominal dose
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inhibition profile. Additional physicochemical and
functional side-by-side characterization of PF-5280014
with trastuzumab-US and trastuzumab-EU using state of
the art robust and orthogonal analytical methodologies
will be published in a separate paper (Ng et al. man-
uscript in preparation).
















PF-05280014 1 22.8 ± 1.90 4,650 ± 258 4,670 346 0.214 109
10b 318 ± 49.4 52,000 ± 1,440 52,400 439 0.191 86.5
100 2,520 ± 219 287,000 ± 11,000 288,000 307 0.347 122
Trastuzumab-US 1 26.3 ± 5.83 4,320 ± 294 4,380 529 0.228 134
10 269 ± 52.7 49,800 ± 1,430 50,000 352 0.200 86.7
100 2,620 ± 332 289,000 ± 12,500 289,000 320 0.346 130
Trastuzumab-EU 1 18.6 ± 8.55 4,730 ± 333 4,800 544 0.208 118
10 281 ± 49.9 51,500 ± 1,380 51,700 392 0.193 85.3
100 2,700 ± 450 298,000 ± 10,300 298,000 290 0.335 116
a The percent extrapolation in the AUC0–? values ranged from 0.104 to 1.54 %;
b nominal dose
Table 3 Comparison of Cmax, AUC0–2,880, and AUC0–? values for PF-05280014, trastuzumab-US, and trastuzumab-EU after a single bolus
intravenous injection
Dose level (mg/kg) Cmax AUC0–2,880 AUC0–?
PF:US PF:EU US:EU PF:US PF:EU US:EU PF:US PF:EU US:EU
All animals
1 0.87 1.23 1.41 1.04 0.915 0.88 1.03 0.91 0.88
10a 1.18 1.13 0.96 1.03 1.00 0.97 1.04 1.00 0.97
100 0.96 0.93 0.97 0.99 0.96 0.97 0.99 0.96 0.97
Data from mice testing positive for ADA excluded
1 0.87 1.23 1.41 1.08 0.98 0.91 1.07 0.97 0.91
10a 1.18 1.13 0.96 1.04 1.01 0.97 1.05 1.01 0.97
100 0.96 0.93 0.97 0.99 0.96 0.97 1.00 0.97 0.97
ADA anti-drug antibodies; EU trastuzumab EU; PF PF-05280014; US trastuzumab-US
a Nominal dose
Table 4 Incidence of mice testing positive for ADA
Biologic Dose level
(mg/kg)
Number of ADA-positive animals/Number of animals tested % Total
incidence
720 h 1,080 h 1,440 h 2,160 h 2,880 h Total
PF-05280014 1 1/5 1/5 3/5 0/5 0/5 5/25 20.0
10b 1/5 0/5 1/5 0/5 0/5 2/25 8.0
100 0/5 0/5 1/4a 0/5 0/5 1/24a 4.2
Trastuzumab-US 1 1/5 1/5 0/5 1/5 2/5 5/25 20.0
10b 0/5 0/5 0/5 0/5 0/5 0/25 0
100 0/5 0/5 0/5 1/5 0/5 1/25 4.0
Trastuzumab-EU 1 0/5 2/5 1/5 1/5 1/5 5/25 20.0
10b 0/5 0/5 1/5 0/5 0/5 1/25 4.0
100 0/5 0/5 0/5 0/5 2/5 2/25 8.0
ADA anti-drug antibodies
a Results from one animal were inconclusive (the animal was positive in screening, negative with titer; however, limited sample volume
precluded confirmation testing or additional analysis); b nominal dose
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Because trastuzumab is a mAb engineered to recognize
the extracellular domain of the human HER2 receptor, it
does not recognize the mouse homolog, neu [16]. There-
fore, PF-05280014, trastuzumab-US, and trastuzumab-EU
would not be expected to interact with the endogenous
mouse receptor, neu, thereby enabling comparative PK
evaluation of non-target- and FcRn-mediated disposition of
these three mAbs [17].
PF-05280014, trastuzumab-US, and trastuzumab-EU
were well tolerated following a single IV dose up to
100 mg/kg. All animals survived to their scheduled ter-
minal blood collection time point, and there were no mAb-
related clinical signs or changes in body weight or body
weight gain over the course of the 4-month study. The
study protocol specified possible clinical pathology, nec-
ropsy, and/or tissue collection as additional safety-related
endpoints if warranted by unscheduled death or euthanasia;
because these did not occur in this study, these additional
safety-related endpoints were not evaluated.
The plasma concentration-time profile of PF-05280014
was similar to those of trastuzumab-US and trastuzumab-EU
at all three doses within the first 24 h and through the
4-month post-dose observation period. In addition, the Cmax
and AUC0–? values for PF-05280014, trastuzumab-US, and
trastuzumab-EU were similar at all doses in this study.
Moreover, the Cmax data reported here are consistent with the
data on the reference products previously submitted to reg-
ulatory agencies [16]. The percent extrapolation in the
AUC0–? values based on the AUC0–2,880 values ranged from
0.081 to 1.28 %, indicating minimal extrapolation. These
data demonstrate that the observed values for AUC0–2,880
accounted for almost all the mAb administered to the mice,
thereby validating the results. The CL and Vss were inde-
pendent of the dose and were comparable across the three
mAbs. The t1/2 for PF-05280014 was similar to those values
for trastuzumab-US and trastuzumab-EU and was consistent
with the data reported for the reference products after a single
IV dose in mice [21]. Additionally, the Cmax values observed
in this study were similar to those previously reported by
trastuzumab [16]. There were also no mAb- or vehicle con-
trol-related clinical signs observed in this study.
The incidence of ADA induction was low (*10%) and
similar across the three mAbs. In mice with ADA, the
plasma concentrations of the administered mAb were lower
in general compared with mice without ADA. Neverthe-
less, there was no impact on the overall PK profile evalu-
ation because of the overall low incidence of ADA within
each dose group. These data indicate that PF-05280014,
trastuzumab-US, and trastuzumab-EU are not highly
immunogenic in mice. Because immunogenicity in animals
has limited predictive value for immunogenicity in humans
[22, 23], these parameters will need to be evaluated in
clinical studies.
5 Conclusion
As the patents of licensed biotherapeutics begin to lapse, there
is an increasing interest in developing biosimilars with the
same target, mechanism of action, safety, and efficacy as the
patented molecules to potentially increase patient access to
valuable therapies at lower cost. Based on the comparative
peptide mapping, in vitro cell growth inhibition profiles and
in vivo PK and ADA data reported in this paper, PF-05280014
appears to be similar to trastuzumab-US and trastuzumab-EU.
These nonclinical data support the clinical development of PF-
05280014 as a potential biosimilar. Subsequent to the non-
clinical study reported here, a phase I study was conducted in
healthy volunteers to determine the biosimilarity between PF-
05280014, trastuzumab-US, and trastuzumab-EU (REFLEC-
TIONS B327-01; NCT01603264). A phase III study is cur-
rently being conducted in metastatic breast cancer patients
(REFLECTIONS B327-02; NCT01989676).
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